MedTrace Logo

Study of SCB01A in Patient With Head and Neck Cancer

NCT02488629 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-06-27

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and efficacy of SCB01A in head and neck cancer.

Conditions

Interventions

DRUG

SCB01A

This study is a single arm, open-label, Phase II trial

Sponsors & Collaborators

  • SynCore Biotechnology Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Hui-Hung Wang, MSc · SynCore Biotechnology Co., Ltd.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02488629 on ClinicalTrials.gov